WOBURN, Mass. , Feb. 25, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported that it will present two scientific posters at the American Academy of Pain Medicine (AAPM) 36 th Annual Meeting to be held February 26 - March 1 in National Harbor , MD.

Record number of SENSUS™ devices sold FDA regulatory clearance for over-the-counter wearable technology to treat chronic pain DPNCheck ® regulatory approval in Japan Year-over-year revenue growth of 16% $8.0 million new capital to support commercial and R&D initiatives WALTHAM, Mass.

Invoiced Value of Quell Shipments Up 19% Over Q3 2016 WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO, NUROW) reported Q4 2016 demand highlights for its Quell ®  Wearable Pain Relief Technology™. During Q4 2016 the invoiced value of Quell shipments totaled

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) reported today that Notices of Allowance has been issued for patents covering key technological features of the Company's Quell ® Wearable Pain Relief Technology™ by the European Patent Office , the Japan Patent Office, and the

NeuroMetrix Reports Successful Marketing Launch of NC-stat(R)|DPNCheck(TM) at the American Diabetes Association 71st Scientific Sessions WALTHAM, Mass., Jul 06, 2011 (BUSINESS WIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it met its planned marketing launch date for NC-stat ®

WOBURN, Mass. , Aug. 20, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell device will be used in an NIH -funded, multi-site randomized controlled trial (RCT) of the efficacy of transcutaneous electrical nerve stimulation (TENS) for chemotherapy-induced

WOBURN, Mass. , June 15, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that Quell technology will be used in a double-blinded, randomized, sham-controlled trial to determine whether transcutaneous electrical nerve stimulation (TENS) is an effective, acceptable and

WOBURN, Mass. , May 19, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced U.S. Food and Drug Administration (FDA) De Novo authorization to market the Quell neuromodulation device as an aid for reducing the symptoms of fibromyalgia in adults with high pain sensitivity.

WOBURN, Mass. , Feb. 24, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell wearable neuromodulation technology will be evaluated for treatment of a fibromyalgia-like syndrome in individuals with post-acute COVID-19 syndrome (PACS, or "long COVID").

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (NASDAQ:NURO) announced a major milestone with over 1 million hours of Quell ®  therapy and health data uploaded to the Quell Health Cloud as of August 1, 2016 . Quell is a wearable therapeutic technology that provides drug-free relief from